Laura Joszt, MA

Controversy surrounds the Advisory Committee on Immunization Practices’ (ACIP) first meeting under new leadership as vaccine skeptics join the panel.

Data from 2019 to 2023 show 9.2% of adults with obesity reported cost-related medication adherence.

In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.

The Beat AML Master Trial found high remission rates and promising safety with triplet therapy in patients with acute myeloid leukemia (AML), according to Ashley Yocum, PhD.

From widening racial health disparities and abortion care restrictions to coverage losses, leadership gaps in addressing social needs, and worsening workforce shortages, the urgent need to improve health equity is underscored in the US.

Delivering value-based cancer care requires overcoming hurdles to access care and tailoring care that prioritizes the quality-of-life metrics the patient values, explained Coral Omene, MD, PhD.

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease remission and significantly improving symptoms like itch and disease severity in adults.

Coverage from IVBM Cleveland, held May 15, 2025.

Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite provider follow-up and efforts to manage side effects, says Hamlet Gasoyan, PhD, Cleveland Clinic.

Early trials found that both garadacimab and sebetralstat were safe when used in patients living with hereditary angioedema, which speaks to the promise of the FDA-approved garadacimab.

High body mass index affects outcomes in acute lymphoblastic leukemia (ALL), highlighting the need for targeted interventions to improve patient survival rates and treatment efficacy.

Knowledge gaps, financial burdens, and skepticism hinder Hispanic men’s participation in the National Diabetes Prevention Program, a study finds.

A new consensus from the National Psoriasis Foundation outlines a clear benchmark for remission to improve treatment decisions and patient outcomes.

Shorter venetoclax durations in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) yielded comparable survival outcomes in a new study, challenging treatment norms.

Pharmacists are being asked to not only manage medications and side effects but also be fiscally responsible for the whole institution and its trickle-down effect on costs, said David Awad, PharmD, BCOP, of Robert Wood Johnson University Hospital.

CEPHEUS trial lead investigator Saad Z. Usmani, MD, MBA, FACP, FASCO, explains how the trial both builds on current knowledge of newly diagnosed multiple myeloma and how transplant-ineligible status may affect therapeutic decision-making.

Pediatric patients with hidradenitis suppurativa have a significantly increased prevalence of chronic medical and psychiatric comorbidities, highlighting the critical need for comprehensive screening and multidisciplinary care.

Explore how health equity and policy shape outcomes, revealing disparities in kidney disease, atopic dermatitis, and cancer care for vulnerable populations.

A global surge in rheumatoid arthritis with local hotspots highlights the need for targeted public health interventions.

The role that artificial intelligence (AI) and other technology can play in care delivery is growing, said Coral Omene, MD, PhD, of Rutgers Cancer Institute and RWJBarnabas Health.

While the tax exclusion for employer-sponsored health care was not included in the House-passed reconciliation bill, it remains a revenue target for Congress, risking inclusion in the Senate's version.

A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.

Marla Black Morgan, MD, looks to the future of research in both myasthenia gravis and rare neurological disorders by expanding data collection and identifying areas of potential difference in patient outcomes.

Initiating fecal immunochemical test (FIT) screening before age 50 can significantly reduce colorectal cancer incidence and mortality, according to one study.

Zilucoplan (Zilbrysq; UCB) is a once-daily subcutaneous C5 complement inhibitor that has demonstrated long-term treatment benefits in patients who have acetylcholine receptor antibody–positive generalized myasthenia gravis (gMG).

Tocilizumab alone and in combination with methotrexate outperformed the latter drug in patients who did not adequately respond to conventional synthetic disease-modifying antirheumatic drugs.

Revumenib shows promise for high-risk patients with acute myeloid leukemia (AML) with specific genetic mutations, demonstrating efficacy with no new safety signals.

Effective toxicity management in oncology requires pharmacists to document interventions clearly and collaborate closely with multidisciplinary teams, says David Awad, PharmD, BCOP.

Burnout is rising sharply in hematology due to emotional strain, long hours, and high patient demands, according to Adela Perolla, MD, PhD, impacting both physician well-being and patient care.

Ola Landgren, MD, PhD, lead investigator of the ADVANCE clinical trial, outlines the study’s goal of advancing modern, minimal residual disease–guided treatment approaches.